Weight loss Mountrao/Zepbound drugs shrink breast cancer tumors

“Obesity is a great risk factor for breast cancer, and although it is very preliminary data, our studies in mice indicate that these new anti -anti -drugs may be a way to reduce the risk of obesity -related breast cancer,” said study author Amanda Kokinsas, BS. Candidate in doctors laboratories. Erine Giles and Kanakaduorga singer at the University of Michigan in Ann Arbur, Michigan.

Current research has shown that the presence of obesity can lead to the worst results of breast cancer compared to those who do not have obesity, and that weight loss can improve the results. However, there are many challenges with traditional weight loss ways.

Kucinskas and its colleagues have benefited from Tirzepatide, one of the new category of effective anti-base drugs that target GLP-1 receptors (glucagon-like peptide 1) and GIP receptors (glucose-based peptide). The researchers have sought to see if Terzopatid will reduce or not breast cancer growth.

This study included the mouse 16 mice. The 9 -week -old C57bl mice are fed up with a 40 % of a 40 % of a high -fat diet that includes a warm environment to urge obesity. At 32 weeks of age, obese mice were randomly assigned to Tirzepatide injection or fake every day for 16 weeks. The sizes of the tumor were measured twice a week.

The researchers found that the anti -body drug reduced body weight and body fat by about 20 % in mice, similar to the amount of weight loss achieved by women on this medicine. They found that this is primarily due to the loss of fatty mass, with a decrease in the weights of the fatty warehouse compared to the controls.

The anti -population drug also reduced the size of the tumor compared to the controls. At the end of the study, the researchers found that the size of the tumor was largely associated with body weight, the total fat mass and the amount of fat stored in the liver.

“While these results are very primary, they point out that this new anti -anti -drug may also have a beneficial effect on the results of breast cancer,” said Kokinsasas.

Current studies are conducted in cooperation with Dr. Steve Hursting Laboratory at North Carolina University in Chapel Hill to separate weight from the impacts of the Azibat.